Total Hip and Knee Arthroplasty in the Pediatric and Adolescent Population: A Systematic Review and Meta-Analysis.

JBJS RevSep 23, 2026 (epub)
Clinical ResearchOrthopedic Surgery

Amir Human Hoveidaei, Mohammad Reza Ramezanpour, Mahyaar Omouri-Kharashtomi et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated total hip arthroplasty (THA) and total knee arthroplasty (TKA) outcomes in patients under 25 years. Analyzing 44 studies with 3,317 patients, the study found that THA had a revision rate of 8.7% and TKA had a revision rate of 12.4%. Functional and quality of life scores improved significantly post-surgery.

Key findings

  • Pooled rates of periprosthetic joint infection after THA were 1.6%.
  • The all-cause revision rate for THA was 8.7%.
  • Pooled rates of aseptic loosening after TKA were 9.9%.
  • Functional scores improved significantly with a standardized mean difference of 4.9 after THA.

Why it matters

Understanding the outcomes of THA and TKA in younger patients is crucial for clinicians, as these procedures can significantly enhance function and quality of life despite higher risks of complications compared to older populations.

Source

PubMed · PMID 42777096

Published in JBJS Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Orthopedic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.